OncoMatch/Clinical Trials/NCT03125577
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Is NCT03125577 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for b-cell malignancies.
Treatment: 4SCAR19 and 4SCAR22 · 4SCAR19 and 4SCAR38 · 4SCAR19 and 4SCAR20 · 4SCAR19 and 4SCAR123 · 4SCAR19 and 4SCAR70 · 4SCAR19 and 4SCAR30 — The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CD123 surface expression
Required: CD19 surface expression
Required: CD20 surface expression
Required: CD22 surface expression
Required: CD30 surface expression
Required: CD38 surface expression
Required: CD70 surface expression
Prior therapy
Cannot have received: car-t cell therapy
Lab requirements
Blood counts
hgb > 80 g/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify